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Abstract 19	
Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease; the 20	
identification of novel targets and development of effective treatment 21	
strategies are urgently needed to improve patient outcomes. Remodeling of 22	
the pancreatic stroma occurs during PDAC development, which drives 23	
disease progression and impairs responses to therapy. The actomyosin 24	
regulatory ROCK1 and ROCK2 kinases govern cell motility and contractility, 25	
and have been suggested to be potential targets for cancer therapy, 26	
particularly to reduce the metastatic spread of tumor cells. However, ROCK 27	
inhibitors are not currently used for cancer patient treatment, largely due to 28	
the overwhelming challenge faced in the development of anti-metastatic 29	
drugs, and a lack of clarity as to the cancer types most likely to benefit from 30	
ROCK inhibitor therapy. In two recent publications, we discovered that 31	
ROCK1 and ROCK2 expression were increased in PDAC, and that increased 32	
ROCK activity was associated with reduced survival and PDAC progression 33	
by enabling extracellular matrix (ECM) remodeling and invasive growth of 34	
pancreatic cancer cells. We also used intravital imaging to optimize ROCK 35	
inhibition using the pharmacological ROCK inhibitor fasudil (HA-1077), and 36	
demonstrated that short-term ROCK targeting, or ‘priming’, improved 37	
chemotherapy efficacy, disrupted cancer cell collective movement, and 38	
impaired metastasis. This body of work strongly indicates that the use of 39	
ROCK inhibitors in pancreatic cancer therapy as ‘priming’ agents warrants 40	
further consideration, and provides insights as to how transient mechanical 41	
manipulation, or fine-tuning the ECM, rather than chronic stromal ablation 42	
	 3	
might be beneficial for improving chemotherapeutic efficacy in the treatment 43	
of this deadly disease.  44	
 45	
Introduction 46	
Despite there being a number of new therapeutics that have been 47	
developed for pancreatic cancer patient therapy, survival remains the lowest 48	
of all solid cancers, with 5-year survival rate being less than 7% and a median 49	
survival of 6 months 1. Despite pre-clinical efforts to develop new therapeutics 50	
2, patient survival has not significantly improved over the last 4 decades, 51	
which highlights not only the need to identify new targets, but also to develop 52	
innovative treatment strategies to improve the outcomes of patients suffering 53	
from this disease. In addition, development of diagnostic tools, for example 54	
based on detection of cancer-derived exosomes 3, to enable early detection of 55	
pancreatic cancer remains a critical challenge for this disease. Pancreatic 56	
ductal adenocarcinoma (PDAC) is characterized by extensive remodeling of 57	
the pancreatic stroma, with increased deposition and crosslinking of 58	
extracellular matrix (ECM) components and poor vascularization compared to 59	
normal pancreas4, 5. Alterations of the biochemical and mechanical properties 60	
of the ECM are known to influence cancer progression, invasion and 61	
responses to chemotherapy	 6-9, however, recent studies assessing the 62	
efficacy of ECM-based pancreatic cancer therapies, for example via inhibition 63	
of Sonic Hedgehog signaling pathway, targeting of lysyl oxidase activity or 64	
inhibition of hyaluronic acid (HA), have yielded conflicting results	4, 10-16. 65	
Rho-associated protein kinases 1 and 2 (ROCK1 and ROCK2) are 66	
master regulators of the actomyosin cytoskeleton and govern force 67	
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generation, cell invasion, proliferation and contractility 17-19. Numerous studies 68	
have established that ROCK inhibition disrupts tumor progression and 69	
metastasis in cell based and in vivo models of various solid cancers 20-23. 70	
However, to date no compounds have progressed into the clinic for cancer 71	
therapy for several reasons. The development of anti-metastatic 72	
chemotherapeutics for clinical use is very challenging due to the need to 73	
detect a reduction in metastasis in patients over sustained periods (likely 74	
years) as a positive outcome 24, in contrast to chemotherapeutics that induce 75	
acute positive responses, such as tumor regression, which can be monitored 76	
in a clinical trial in a defined and relatively brief time period 24. Furthermore, 77	
the absence of correlations between defined genetic alterations, such as 78	
ROCK1 or ROCK2 mutations, with ROCK inhibitor sensitivity means that 79	
there is no simple genetic test for convenient patient stratification. As a result, 80	
ROCK inhibition has not been adopted as a cancer chemotherapy. In this 81	
commentary, we describe our recent findings 25, 26 demonstrating that ROCK 82	
activity promotes pancreatic cancer invasive growth via ECM remodeling. We 83	
also highlight how transient ROCK inhibition, or mechanical ‘priming’ with the 84	
pharmacological inhibitor fasudil affects tumor tissue tension, which in turn 85	
improves chemotherapy efficacy in primary and secondary tumor sites, while 86	
also disrupting collective movement of metastatic cancer cells 26. Lastly, we 87	
discuss potential translation of our findings into the clinic for pancreatic cancer 88	
therapy, where balancing cellular contractility via transient ROCK inhibition, 89	
rather than long-term ablation of the matrix, enables re-establishment of the 90	
normal mechanical features of the stroma.  91	
 92	
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ROCK activity promotes PDAC progression. 93	
Genomic analyses have previously shown that the ROCK1 gene is 94	
amplified in 15% of pancreatic patient tumors 27, however the role of ROCK-95	
mediated actomyosin contractility in PDAC had not been clearly established. 96	
To address this, we assessed ROCK expression in a patient tissue microarray 97	
(78 samples from patients with pancreatic cancers and 5 healthy human 98	
pancreas) and in human TCGA datasets, and determined that ROCK1 and 99	
ROCK2 expression increase with tumor stage and grade 25. In line with this, 100	
genomic alterations or mRNA amplification of ROCK1 and/or ROCK2 were 101	
found to be positively correlated with poorer survival, suggesting that ROCK 102	
signaling promotes pancreatic cancer progression 25.  103	
To further understand how ROCK influences the fate and behavior of 104	
pancreatic cancer cells, Cre-recombinase was expressed from the pancreatic 105	
epithelial selective Pdx1 promoter to induce pancreas-targeted recombination 106	
of  LOX-STOP-LOX (LSL)-KrasG12D/+and LSL-Trp53R172H/+ (KPC) alleles in 107	
mice, which spontaneously develop PDAC that closely resembles human 108	
pancreatic cancer 28, 29. In addition, KPC mice were crossed with LSL-109	
ROCK2:ER mice 30 to conditionally activate ROCK2 during PDAC 110	
progression. This model closely recapitulates the genomic features of human 111	
PDAC, where an initiating KrasG12D mutation is found in almost 90% of patient 112	
tumors, while the p53R175H mutation is found in 50-75% of patient tumors	 31. 113	
Consistent with the observed increased ROCK2 protein levels in advanced 114	
PDAC stages,  as well as the correlation between increased ROCK1 and 115	
ROCK2 mRNA expression, along with a potentially activating truncation 116	
mutation (I383F-frameshift deletion; TCGA-HZ-8005-01), with poor survival 117	
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from the TCGA human dataset, conditional ROCK2 activation was associated 118	
with reduced PDAC mouse survival. Conditional ROCK2 activation in non 119	
metastatic PDAC cells isolated from genetically modified mice promoted 120	
pancreatic cancer cell invasion into 3D collagen matrices (see schematic 121	
representation of ROCK inhibition at the cellular level, Fig. 1A) 25. 122	
Interestingly, analyses of cell-ECM interactions using Second Harmonic 123	
Generation (SHG) imaging, a label free imaging technique used to detect non-124	
centrosymmetric entities such as crosslinked collagen fibers, or tannic acid-125	
glutaraldehyde fixation of collagen fibers for transmission electron 126	
microscopy, revealed that ROCK activation induced extensive remodeling of 127	
the collagen matrix surrounding invading cancer cells 25.  128	
While ROCK is well known to induce force generation via its action on 129	
actomyosin structures 19, ROCK signaling also induces gene transcription 32. 130	
To identify ROCK induced gene expression changes, we performed RNA 131	
sequencing and identified 285 genes that were consistently and significantly 132	
found to be changed greater than twofold relative to control cells. 133	
Interestingly, conditional ROCK activation increased expression of 134	
metalloproteinases (MMP) Mmp10 and Mmp13, which was associated with 135	
increased release of these MMPs into the surrounding environment (see 136	
schematic representation of ROCK inhibition at the cellular level, Fig. 1A). 137	
These results indicated that ROCK mediates collagen remodeling by 138	
pancreatic cancer cells via transcription, synthesis and release of MMPs, in 139	
line with previous observations in melanoma cells 33, and in pancreatic cancer 140	
cells in which dasatinib-induced reduction of KPC cell migration was 141	
correlated with reduced production of MMP2 and MMP9 34. We also 142	
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determined that ROCK-mediated remodeling of the surrounding matrix 143	
facilitated invasive growth of pancreatic cancer cells (see schematic 144	
representation of ROCK inhibition at the cellular and whole-body levels, Fig. 145	
1A, B). These findings highlight the ability of cancer cells to adapt to the 146	
mechanical environment and to remodel the ECM to support their aberrant 147	
growth. These cell-based observations were further extended in KPC mice, 148	
where ROCK inhibition with fasudil significantly prolonged survival, and 149	
reduced collagen remodeling (see schematic representation of ROCK 150	
inhibition at the cellular and whole-body levels Fig. 1A, B) 25. Together, these 151	
results shed light on novel roles of ROCK in driving pancreatic cancer 152	
progression, suggesting that targeting ROCK might be beneficial for the 153	
clinical management of the disease.    154	
 155	
Transient ROCK inhibition with fasudil disrupts pancreatic cancer. 156	
Although ROCK-driven cell contractility and stromal remodeling are 157	
known to play crucial roles in cancer progression 7, 19, 35, ROCK inhibitors and 158	
ECM-based therapies have yet to be translated to the clinic. In our recent 159	
publication, we assessed the efficacy of fasudil to impair PDAC progression 160	
and to influence cell responses to chemotherapy	 26. Fasudil is a ROCK 161	
inhibitor currently used clinically as a monotherapy for the treatment of 162	
cerebral vasospasm 36, and Fasudil has also been shown to inhibit, in a less 163	
potent manner than for ROCK, other kinases such as PKA, PKC and MLCK	164	
37. Meta-analysis of post-marketing surveillance data (>3,000 patients) has 165	
demonstrated the safety of fasudil for clinical use in humans 38, which 166	
prompted us to assess the repurposing of fasudil for the treatment of 167	
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pancreatic cancer. We combined mouse and stratified patient-derived models 168	
of pancreatic cancer with biosensor FLIM-FRET intravital imaging to monitor 169	
the effect of ROCK inhibition in real-time and in live tissues 39-42. Using an 170	
early, transient ‘priming’ regimen, where fasudil was administered for 3 days 171	
prior to chemotherapy, in line with its treatment regimen in patients with stable 172	
angina 43, we demonstrated that short-term ROCK inhibition with fasudil 173	
synchronized pancreatic cancer cell cycle progression, and rendered them 174	
more sensitive to subsequent treatment with anti-microtubule drugs and 175	
standard-of-care chemotherapy, both in primary tumors and metastatic sites  176	
(see schematic representation of ROCK inhibition at the whole-body level, 177	
Fig. 1B) 26. We also observed that ‘priming’ with fasudil in the adjuvant setting 178	
disturbed coordinated cancer cell movement and impaired metastatic 179	
colonization in the liver (see schematic representation of ROCK inhibition at 180	
the whole-body level, Fig. 1B).  181	
 182	
Assessment of the effect of ‘priming’ on key metastatic events revealed 183	
that ROCK inhibition rendered circulating tumor cells more sensitive to shear 184	
stress to which they are subjected in the blood circulation and in turn impaired 185	
their ability to extravasate and colonize host tissues (see schematic 186	
representation of ROCK inhibition at the whole-body level, Fig. 1B), consistent 187	
with previous studies 44, 45. Additionally, analysis of collective cell movement, 188	
or streaming, upon ‘priming’ suggested that transient ROCK inhibition 189	
impaired coordinated cell migration and 3D cell movement of the metastatic 190	
emboli in the liver (see schematic representation of ROCK inhibition at the 191	
whole-body level, Fig. 1B) 26, possibly due to disrupted durotaxis - where cell 192	
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movement is directed by stiffness gradients - in the metastatic niche 46. The 193	
observed reduction of coordinated PDAC cell spread that we observed upon 194	
ROCK inhibition was also in line with previous work highlighting how the Rho-195	
ROCK-LIMK pathway leads tumor cell invasion by driving path generation 47. 196	
ROCK inhibition was also found to reduce the ability of metastatic cells to 197	
remodel the host ECM and to create a favorable environment to support their 198	
growth in a distant site (see schematic representation of ROCK inhibition at 199	
the whole-body level Fig. 1B), as recently demonstrated in pancreatic cancer 200	
and melanoma 48-50. Assessment of the effects of ‘priming’ with fasudil on the 201	
stroma demonstrated that transient ROCK inhibition reduced ECM remodeling 202	
and tissue stiffness, thereby altering integrin signaling and depriving cancer 203	
cells of mechanical cues provided by the matrix 26. In addition, decompression 204	
of the tumor tissue upon ‘priming’ with fasudil was accompanied by relaxation 205	
and increased permeability of the tumor vasculature, as assessed by the 206	
imaging of quantum dots diffusing from blood vessels and into tumor tissue 207	
(see schematic representation of ROCK inhibition at the whole-body level Fig. 208	
1B and Movie 1) 26. This is in line with the current clinical use of fasudil for the 209	
treatment of cerebral vasospasm 36, 43 and with recent work demonstrating 210	
that ROCK regulates vascular patency, or obstruction 51. Our findings 211	
therefore demonstrate that fasudil has a dual effect on both the ECM and the 212	
intratumoral vasculature, which together increased drug delivery and 213	
improved cancer cell responses to chemotherapy. This aligns with recent 214	
stromal-based strategies in metastatic colorectal cancer, where the 215	
combination of anti-VEGF therapy and anti-hyaluronic acid treatment 216	
significantly improved chemotherapy efficacy and prolonged survival 217	
	 10	
compared to anti-VEGF therapy alone 52. Our work also indicates that rather 218	
than chronic treatment, which has a greater potential for adverse effects and 219	
toxicity 11, 14, acute fasudil treatment to induce transient mechanical ‘priming’ 220	
was sufficient to re-equilibrate the pancreatic tumor stroma and to impair 221	
PDAC progression. Together, our findings demonstrate that ‘priming’ with 222	
fasudil might be beneficial both in the neo-adjuvant and adjuvant settings, 223	
which strongly suggests that further clinical assessment of fasudil in 224	
combination with standard-of-care chemotherapy, such as Gemcitabine and 225	
Abraxane, is warranted to improve PDAC patient outcomes.  226	
 227	
Balancing cell contractility: a new approach to treat pancreatic cancer. 228	
While numerous studies have demonstrated that extensive 229	
transformation of the pancreatic stroma occurs during cancer development 5, 230	
53, previous work assessing ECM-based therapies have yielded conflicting 231	
data regarding the efficacy of stromal therapies in pancreatic cancer. As such, 232	
while pharmacological inhibition of the Hedgehog (Hh) signaling pathway 4, 233	
hyaluronic acid (HA) deposition 13, 15 or lysyl oxidase (LOX) activity 12 resulted 234	
in impaired tumor growth and increased survival in mouse models of 235	
pancreatic cancer, genetic ablation of Hh signaling 14 or myofibroblasts 11 236	
resulted in decreased survival. Importantly, ablation of fibrosis triggered 237	
adverse effects on the pancreatic stroma, such as profound alterations of the 238	
immune microenvironment, which in turn promoted cancer progression 11, 14. 239	
Identification of new ECM targets and development of innovative therapeutic 240	
regimens to ‘fine-tune’ and manipulate the pancreatic stroma are therefore 241	
needed to improve pancreatic cancer patient outcomes. We believe that this 242	
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balance is key to future development of stromal targeting strategies for this 243	
disease.  244	
Our two recent publications 25, 26 establish ROCK as a key regulator of 245	
matrix remodeling in pancreatic cancer, both via generation of contractile 246	
force, and regulation of MMP synthesis and release into the surrounding 247	
matrix (see schematic representation of ROCK inhibition at the cellular level, 248	
Fig. 1A). These findings align with recent work in pancreatic cancer 249	
demonstrating that the JAK/ROCK/STAT3 signaling pathway governs cancer 250	
cellular tension and promotes tumor progression via remodeling of the 251	
surrounding matrix in close proximity to the tumor 53. Our observations also 252	
highlight the intricate effects of ROCK-induced remodeling of the ECM. While 253	
prolonged exposure to fasudil significantly increased mechanical constraints 254	
and reduced tumor growth in the KPC model, potentially via reduced release 255	
of MMPs into the environment, transient ‘priming’ with fasudil led to reduced 256	
ECM crosslinking and relaxation of tumor tissue. This aligns with the 257	
emerging concept that the pancreatic stroma can both promote and restrain 258	
disease progression 8, 16. Importantly, our work provides pre-clinical evidence 259	
that fine-tuning the ECM via transient ROCK inhibition using our ‘priming’ 260	
approach might provide new avenues for the treatment of pancreatic cancer. 261	
Potential hypotensive effects of ROCK inhibition with fasudil might be 262	
expected given its use for cerebral vasospasm, however the actions on the 263	
vasculature that we observe also have the potential beneficial effect of 264	
increasing drug delivery. Consistent with recently published work from the 265	
Weaver lab, we report no significant change in patient survival associated with 266	
bulk tumor stroma 26, 53, however our study demonstrates a graded response 267	
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to the ‘priming’ strategy in patient-derived xenografts that had been stratified 268	
based on their ECM signature 26. Where in tumors with high ECM content, 269	
‘priming’ with fasudil greatly improved cancer cell responses to chemotherapy, 270	
delayed metastasis and approximately doubled survival compared to 271	
chemotherapy alone, this had a modest effect in tumors with low ECM content 272	
26. This observation suggested that initial collagen content could be used as a 273	
surrogate biomarker alone, or because of the dual effects of fasudil ‘priming’ 274	
on the ECM and the intratumoral vasculature, in combination with tumor 275	
vasculature markers, such as CD31 (cluster of differentiation 31), to identify 276	
patients most likely to benefit from transient ROCK inhibition prior to 277	
chemotherapy (see schematic representation companion biomarker strategy, 278	
Fig. 1C). Additionally, non-invasive PET-reporters of fibrotic tissue are being 279	
developed for diagnosis of pulmonary fibrosis, which could be repurposed in 280	
this context	54. We propose that the repurposing of a low-cost, off-patent drug 281	
such as fasudil as a ‘priming’ agent might be beneficial for pancreatic cancer 282	
therapy. In addition, novel ROCK inhibitors such as AT13148, KD025 or 283	
CCT129254, currently in the clinical testing pipeline as anti-fibrotic agents, or 284	
in phase I clinical trial for the treatment of solid tumors (AT13148, 285	
NCT01585701 55) could also have similar applications 56-59. Remodeling of the 286	
stroma has also been reported to occur in other solid cancers and to influence 287	
disease progression 7, 48, 60, 61	62	63. Therefore, we envisage that fine-tuning the 288	
ECM via ROCK inhibition prior to standard-of-care therapies might lead to 289	
substantial therapeutic benefits in additional diseases.  290	
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 488	
Figure and movie legends 489	
Figure 1 Schematic of the roles of ROCK and ROCK inhibition in 490	
pancreatic cancer: from cell-to-global effects to translation to patients. 491	
A. ROCK inhibition at the cellular level impairs ECM remodeling via 492	
decreased MMP release and impaired contractility. B. ROCK inhibition at the 493	
whole body, global level. Schematic representation of the effects of ROCK 494	
inhibition in primary tumor tissue (left hand panel), on circulating tumor cells 495	
(CTC, middle panel) and at secondary sites (right hand panel). Adapted from 496	
(Vennin et al., Science Translational Medicine 2017)	26. Reprinted with 497	
permission from AAAS. C. Combination of ECM and vasculature markers as 498	
companion biomarkers for priming strategy. Left hand panel: Schematic 499	
representation of in-house automated Second Harmonic Generation (SHG) 500	
analysis of the ECM in the ICGC human TMA cohort, with examples of SHG 501	
signals in cores (triplicates) from patients with high, medium, or low SHG 502	
signal. Right hand panel: representative images of quantum dots and CD31 503	
(cluster of differentiation 31) staining in tumors with high and low vascularity. 504	
Adapted from (Vennin et al., Science Translational Medicine 2017) 26. 505	
Reprinted with permission from AAAS. 506	
 507	
Movie 1: Intravital imaging of quantum dots circulating in tumor associated 508	
blood vessels and diffusing into the surrounding tumor tissue. Red: Quantum 509	
Dot, Blue: Collagen fibers (SHG signal). 510	

